Get started
NEUROCRINE BIOSCIENEUROCRINE BIOSCIENEUROCRINE BIOSCIE

NEUROCRINE BIOSCIE

No trades
See on Supercharts
Overview
Financials News Ideas Forecast

NB3 chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪12.65 B‬CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
37.849
Basic EPS (TTM)
3.395CHF
Net income (FY)
‪210.23 M‬CHF
Revenue (FY)
‪1.59 B‬CHF
Shares float
‪98.08 M‬
Beta (1Y)
0.54

About Neurocrine Biosciences, Inc.

Sector
Health Technology
CEO
Kevin Charles Gorman
Headquarters
San Diego
Website
neurocrine.com
Employees (FY)
‪1.4 K‬
Founded
1992
FIGI
BBG00LVF08S7
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Sparks

Curated watchlists where NB3 is featured.

See all sparks 

Frequently Asked Questions

The current price of NB3 is 134.825 CHF — it has increased by 7.74% in the past 24 hours. Watch NEUROCRINE BIOSCIE stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange NEUROCRINE BIOSCIE stocks are traded under the ticker NB3.
NB3 stock has risen by 7.74% compared to the previous week, the month change is a 20.82% rise, over the last year NEUROCRINE BIOSCIE has showed a 17.48% increase.
We've gathered analysts' opinions on NEUROCRINE BIOSCIE future price: according to them, NB3 price has a max estimate of 195.87 CHF and a min estimate of 100.65 CHF. Watch NB3 chart and read a more detailed NEUROCRINE BIOSCIE stock forecast: see what analysts think of NEUROCRINE BIOSCIE and suggest that you do with its stocks.
NB3 reached its all-time high on May 8, 2024 with the price of 134.825 CHF, and its all-time low was 111.591 CHF and was reached on Jan 3, 2024. View more price dynamics on NB3 chart.
See other stocks reaching their highest and lowest prices.
NB3 stock is 7.19% volatile and has beta coefficient of 0.54. Track NEUROCRINE BIOSCIE stock price on the chart and check out the list of the most volatile stocks — is NEUROCRINE BIOSCIE there?
Today NEUROCRINE BIOSCIE has the market capitalization of ‪12.59 B‬, it has increased by 1.74% over the last week.
Yes, you can track NEUROCRINE BIOSCIE financials in yearly and quarterly reports right on TradingView.
NEUROCRINE BIOSCIE is going to release the next earnings report on Jul 30, 2024. Keep track of upcoming events with our Earnings Calendar.
NB3 earnings for the last quarter are 0.38 CHF per share, whereas the estimation was 0.99 CHF resulting in a −61.75% surprise. The estimated earnings for the next quarter are 0.99 CHF per share. See more details about NEUROCRINE BIOSCIE earnings.
NEUROCRINE BIOSCIE revenue for the last quarter amounts to ‪464.86 M‬ CHF despite the estimated figure of ‪462.24 M‬ CHF. In the next quarter revenue is expected to reach ‪494.04 M‬ CHF.
NB3 net income for the last quarter is ‪39.15 M‬ CHF, while the quarter before that showed ‪124.35 M‬ CHF of net income which accounts for −68.52% change. Track more NEUROCRINE BIOSCIE financial stats to get the full picture.
No, NB3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 16, 2024, the company has ‪1.40 K‬ employees. See our rating of the largest employees — is NEUROCRINE BIOSCIE on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEUROCRINE BIOSCIE EBITDA is ‪444.65 M‬ CHF, and current EBITDA margin is 22.05%. See more stats in NEUROCRINE BIOSCIE financial statements.
Like other stocks, NB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEUROCRINE BIOSCIE stock right from TradingView charts — choose your broker and connect to your account.